吉西他滨联合顺铂在进展期胰腺癌动脉灌注化疗中的应用  

Application of transarterial infusion chemotherapy with gemzar plus cisplatin in advancing pancreatic cancer

作　　者：黄源义[1] 龚春城[1] 谢孝平[1] 

机构地区：[1]华中科技大学同济医学院附属荆州医院,湖北荆州434020

出　　处：《中国肿瘤临床与康复》2006年第1期41-42,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的评价吉西他滨（商品名健择）联合顺铂动脉灌注治疗进展期胰腺癌的疗效和毒副反应。方法对21例进展期胰腺癌患者采用吉西他滨联合顺铂动脉灌注化疗，治疗间隔时间为3周，随访观察患者临床受益反应、肿瘤情况、毒副作用及生存时间。结果21例患者的临床受益率为42．9％．客观缓解率为19．1％，中位疾病进展时间为4．2个月，中位生存时间为9．2个月。毒副反应较常见，但多为WHOⅠ-Ⅱ级。结论经动脉灌注吉西他滨和顺铂治疗进展期胰腺癌可获得较好的临床受益反应，无严重毒副反应。Objective To evaluate the efficacy and toxicity of gemzar plus cisplatin by transarterial infusion in advancing pancreatic cancer. Methods Twenty-one patients with advancing pancreatic cancer were treated with transarterial infusion chemotherapy with gemzar plus cisplation, once every three weeks. Then the tumor response rate, clinical benefit, survival time and toxicity were observed. Results A clinical benefit was obtained in 9 patients （42.9%）. The tumor response rate was 19.1%. The median time of disease progression was 4.2 months with median survival time of 9.2 months. The toxicity in most of the patients was grade Ⅰ -Ⅱ according to WHO classification. Conclusions Transarterial infusion chemotherapy with a combination of gemzar and cisplatin appears to have good clinical benefit. There was no severe side effects.

关 键 词：胰腺肿瘤/化学疗法 吉西他滨 动脉灌注 

分 类 号：R735.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]